Journals / MN Kardiyoloji / 2000 / Cilt: 7 - Sayı: 3

Significance of tissue factor procoagulan activity as a risk factor for PTCA and stent restenosis

Perkütan transluminal koroner anjiyoplasti ve stent uygulanan hastalarda doku faktör prokoagülan aktivitesinin restenoz gelişimindeki rolü

Pages
214–218
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: Our study is the first in vivo study demonstrating that TF procoagulant activity may have a role in the genesis of restenosis after PTCA and stent implantation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM OF THE STUDY: Increased tissue factor (TF) activity has been detected in atherosclerotic vessels.
📊
Key Findings & Data:METHODS: Study group consisted of 61 patients with stable angina pectoris who underwent successful PTCA (n=20) and stent implantation (n=41).
💡
Conclusion & Impact:CONCLUSION: Our study is the first in vivo study demonstrating that TF procoagulant activity may have a role in the genesis of restenosis after PTCA and stent implantation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Koroner anjiyografi · Anjiyoplasti · transluminal

Abstract

AIM OF THE STUDY: Increased tissue factor (TF) activity has been detected in atherosclerotic vessels. Experimental data suggest that TF might induce neointimal hyperplasia. Thus, we investigated the effect of TF procoagulant activity (TF-PCA) on the genesis of restenosis after percutaneous transluminal coronaıy angioplasty (PTCA) and stent implantation. METHODS: Study group consisted of 61 patients with stable angina pectoris who underwent successful PTCA (n=20) and stent implantation (n=41). The TF-PCA was studied from whole blood cell samples using "two-stage clotting assay" just before the intervention and repeated at 3rd and 24th hours after the intervention. Follow-up coronary angiography was performed 4-6,months after intervention and quantitevely measured luminal narrowing >50% was regarded as restenosis. RESULTS: Restenosis was detected in 20 patients (33%). Baseline, 3rd and 24th hour TF-PCA were significantly higher in patients who have restenosis (respectively 35±20, 32±11, 32±12 U/mL in restenosis group and 24±14, 25±11, 25±10 U/mL in no-restenosis group, p=0.006). There were no significant variation in TF-PCA at baseline, 3rd and 24th hour in each group of patients (p=0.651). In patients who underwent stent implantation, 3rd hour TF-PCA level were significantly higher in patients with restenosis (35±11 vs 27±12 U/mL, p=0.046). In PTCA group baseline (35±25 and 20±9 U/mL, p=0.042) and 24th hour (31 ±11 and 20±5 U/mL, p=0.009) TF-PCA level were higher in patients with restenosis. CONCLUSION: Our study is the first in vivo study demonstrating that TF procoagulant activity may have a role in the genesis of restenosis after PTCA and stent implantation.

Özet

AMAÇ: Son zamanlarda aterosklerotik plakta doku faktör aktivitesinin arttığını ve doku faktörünün neointimal proliferasyonu indüklediğini gösteren bulgular elde edilmiştir. Çalışmamızda perkütan transluminal koroner anjiyoplasti (PTCA) ve stent uygulanan hastalarda doku faktör prokoagülan aktivitesinin (DF-PKA) restenoz gelişimindeki rolü araştırıldı. YÖNTEM: Başarılı PTCA (n=20) ve stent (n=41) uygulanan 61 kararlı angına pektoris hastası çalışmaya alındı. İşlemden hemen önce (bazal) ve işlemden 3 ve 24 saat sonra olmak üzere 3 kez periferik kan örnekleri alınarak DF-PKA ölçümü yapıldı. DF-PKA ölçümü, rekombinan FVIIa kullanılarak "çift aşamalı pıhtılaşma ölçüm testi" esasına göre yapıldı. Hastalar 4-6 ay sonra yapılan kontrol koroner anjiyografiyle restenoz açısından değerlendirildi. Koroner anjiyografide işlem uygulanan arter segmentinde %50 ve üzerindeki darlık restenoz olarak kabul edildi. BULGULAR: Kontrol koroner anjiyografide 20 hastada (%33) restenoz saptandı.. Restenoz gelişen vakalardaki bazal, 3. ve 24. Saatteki DF-PKA değerlen restenoz gelişmeyenlere göre anlamlı olarak daha fazla bulundu (bazal, 3. ve 24. saat değerleri restenoz gelişen grupta sırasıyla 35.±20, 32±11, 32±12 U/mL, restenoz gelişmeyen grupta 24±14, 25±11, 25±10 U/mL, p=0.006). Her bir gruptaki 3 değerin zamana göre anlamlı değişini göstermediği saptandı (p=0.651). Stent uygulanan hastalarda restenoz gelişenlerde 3. saat DF-PKA ölçümü restenoz gelişmeyenlere göre anlamlı olarak daha yüksek idi (35±11 ve 27±12 U/mL, p=0.046). PTCA uygulanan hastalarda restenoz gelişenlerde bazal (35±25 ve 20±9 U/mL, p=0.042) ve 24. saatteki (31±l1 ve 20±5 U/mL, p=0.009) DF-PKA değerleri anlamlı olarak daha yüksek bulundu. SONUÇ: DF-PKA düzeyinin PTCA ve stent restenozu gelişiminde rolü olduğu sonucuna varıldı. Çalışmamız PTCA ve stent uygulaması sonrası restenoz gelişiminde DF-PKA 'nin rolü olduğunu gösteren ilk in vivo çalışmadır.

🔖

Cite This Article

TUTAR, E., ÖZCAN, M., KILIÇKAP, M., GÜLEÇ, S., DİNÇER, İ., KUMBASAR, D., DALVA, K., PAMİR, G., ORAL, D. (2000). Significance of tissue factor procoagulan activity as a risk factor for PTCA and stent restenosis. MN Kardiyoloji, Cilt: 7 - Sayı: 3, 214–218. https://ajindex.com/articles/298142

References (15)

  1. Hong MK, Mehran R, Mintz GS, Leon MB. Restenosis after coronary angioplasty. Current Problems in Cardiology 1997;22:1-36.
  2. Hamon M, Bauters C, McFadden EP, Wemert N, Lablanche M, Dupuis B, Bertrand ME. Restenosis after coronary angioplasty. Eur Heart J 1995;16(Suppl l):33-48.
  3. Moliterno DJ, Topol EJ. Restenosis: Epidemiology and Treatment. In: Textbook of Cardiovascular Medicine, Ed: Topol EJ, Lippincott- Raven Publ, 1998; chapter 75:2065-100.
  4. Dangas G, Fuster V. Management of restenosis after coronary intervention. Am Heart J 1996; 132:428-36.
  5. Edelman ER, Rogers C. Pathobiologic responses to stenting. Am J Cardiol 1998;81(7):4-6.
  6. Tremoli E, Camera M, Toschi V, Colli. S. Tissue factor in atherosclerosis. Atherosclerosis 1999; 144:273-83.
  7. Kirchhofer D, Banner DW. Molecular and structural advances in tissue factor-dependent coagulation. TCM 1997;7:316-24.
  8. Hatakeyama K, Asada Y, Marutsuka K, Sato Y, Kamikubo Y, Sumiyoshi A. Localization and activity of tissue factor in human aortic atherosclerotic lesions. Atherosclerosis 1997;133:213-9.
  9. Hatakeyama K, Asada Y, Marutsuka K, Kataoka H, Sato Y, Sumiyoshi A. Expression of tissue factor in the rabbit aorta after balloon injury. Atherosclerosis 1998;139:265-71.
  10. Carmeliet P, Collen D. Molecules in focus Tissue factor. Int J Biochem Cell Biol 1998;30:661-7.
  11. Key NS, Slungaard A, Dahdelet L, Nelson SC, Moertel C, Styles LA, Kuypers FA, Bach RR Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998:91:4216-23.
  12. Asada Y, Hara S, Tsuneyoshi A, Hatakeyama K, Kisanuki A, Marutsuka K, Sato Y, Kamikubo Y, Sumiyoshi A. Fibrin-rich and platelet-rich thrombus formation on neointima: recombinant tissue factor pathway inhibitor prevents fibrin formation and neointimal development following repeated balloon injury of rabbit aorta. Thromb Haemost 1998;80(3):506-11.
  13. Oltrona L, Speidel CM, Recchia D, Wickline SA, Eisenberg PR, Abandschein DR. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation 1997;96:646-52.
  14. Jang Y, Guzman LA, Lincoff M, Gottsauner-Wolf M, Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ. Inluence of blockade at spesific levels of the coagulation cascade on restenosis in a rabbir atherosclerosis femoral artery injury model. Circulation 1995;92-3041-50.
  15. Kamikubo Y-l, Nakahara Y, Takemoto S, Hamuro T, Miyamoto S, Funatsu A. Human recombinant tissue-factor pathway inhibit